Isomerase Therapeutics Limited
08335008
Healthy
No risk factors detected.
Details
Compliance
Last accounts
31/12/2025
small
Next accounts due
30/09/2027
Confirmation statement
Last: 31/10/2025
Due 14/11/2026
Industry
Officers
director · Since 18/12/2012
NON-EXECUTIVE DIRECTOR
BRITISH · UNITED KINGDOM · Age 57
Also on 1 other board
Persons with Significant Control
Former PSCs
Dr Steven James Moss
Ceased 05/03/2025
Matthew Alan Gregory
Ceased 05/03/2025
CompanyRankvs 44+ SIC 72110 peers88
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Key FinancialsYear ending 31/12/2025
Net Worth
£2.7M
Balance sheet strength
Cash
£1.8M
Cash in the bank
Net Current Assets
£2.4M
Working capital
Current Assets
£2.6M
Current Liabilities
£222k
Fixed Assets
£342k
Debtors
£747k
Balance Sheet
EstimatesDerived
| Year | Current Ratio | Implied Profit |
|---|---|---|
| 2025 | 11.69 | -£198k |
| 2024 | 5.97 | — |
Derived from filed accounts. Not audited figures.